Literature DB >> 9502407

Interleukin-12 expression is focally enhanced in the gastric mucosa of pediatric patients with Crohn's disease.

D Berrebi1, M Besnard, G Fromont-Hankard, R Paris, J F Mougenot, P De Lagausie, D Emilie, J P Cezard, J Navarro, M Peuchmaur.   

Abstract

The stomach is frequently involved in children suffering from Crohn's disease (CD). Diagnosis of specific gastritis may be difficult when granulomas are absent. We have used in situ hybridization to examine the expression of interleukin (IL)-12, a key cytokine in the Th1 response. IL-12 p35 and p40 antisense probes were used to examine ileal specimens from 9 children with CD and gastric biopsies from 24 children (13 with CD, 6 with Helicobacter pylori chronic gastritis, and 5 with a normal gastric mucosa). In all patients with CD, many clusters of IL-12-positive cells were present in the lamina propria. This was the case in the ileal specimens as well as in gastric mucosa showing granulomatous gastritis or nongranulomatous gastritis. The same distribution patterns were found for the IL-12 p35 and p40. In three patients with Helicobacter pylori gastritis, few scattered IL-12-positive cells were found. No positive cells were found in the normal gastric mucosa. The focally enhanced IL-12 expression in the gastric mucosa of pediatric patients with CD, with or without specific lesions, suggests that both are indeed linked to the disease and supports the major part of IL-12 in initiating and maintaining of the cascade resulting in the Th1 responses.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9502407      PMCID: PMC1858403     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  27 in total

1.  In situ Rantes and interferon-gamma gene expression in pediatric small bowel Crohn's disease.

Authors:  D Berrebi; A Banerjee; R Paris; F Potet; Y Aigrain; D Emilie; J P Cezard; J P Hugot; J Navarro; M Peuchmaur
Journal:  J Pediatr Gastroenterol Nutr       Date:  1997-10       Impact factor: 2.839

2.  Focally enhanced gastritis: a frequent type of gastritis in patients with Crohn's disease.

Authors:  G Oberhuber; A Püspök; C Oesterreicher; G Novacek; C Zauner; M Burghuber; H Vogelsang; R Pötzi; M Stolte; F Wrba
Journal:  Gastroenterology       Date:  1997-03       Impact factor: 22.682

3.  IL-12-deficient mice are defective but not devoid of type 1 cytokine responses.

Authors:  J Magram; J Sfarra; S Connaughton; D Faherty; R Warrier; D Carvajal; C Y Wu; C Stewart; U Sarmiento; M K Gately
Journal:  Ann N Y Acad Sci       Date:  1996-10-31       Impact factor: 5.691

4.  Cooperation of natural killer cell stimulatory factor/interleukin-12 with other stimuli in the induction of cytokines and cytotoxic cell-associated molecules in human T and NK cells.

Authors:  M Aste-Amezaga; A D'Andrea; M Kubin; G Trinchieri
Journal:  Cell Immunol       Date:  1994-07       Impact factor: 4.868

5.  IL-12 induces the production of IFN-gamma by neonatal human CD4 T cells.

Authors:  C Y Wu; C Demeure; M Kiniwa; M Gately; G Delespesse
Journal:  J Immunol       Date:  1993-08-15       Impact factor: 5.422

6.  Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease.

Authors:  P Parronchi; P Romagnani; F Annunziato; S Sampognaro; A Becchio; L Giannarini; E Maggi; C Pupilli; F Tonelli; S Romagnani
Journal:  Am J Pathol       Date:  1997-03       Impact factor: 4.307

7.  T helper 1 effector cells specific for Helicobacter pylori in the gastric antrum of patients with peptic ulcer disease.

Authors:  M M D'Elios; M Manghetti; M De Carli; F Costa; C T Baldari; D Burroni; J L Telford; S Romagnani; G Del Prete
Journal:  J Immunol       Date:  1997-01-15       Impact factor: 5.422

Review 8.  Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994.

Authors:  M F Dixon; R M Genta; J H Yardley; P Correa
Journal:  Am J Surg Pathol       Date:  1996-10       Impact factor: 6.394

9.  Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells.

Authors:  G Monteleone; L Biancone; R Marasco; G Morrone; O Marasco; F Luzza; F Pallone
Journal:  Gastroenterology       Date:  1997-04       Impact factor: 22.682

10.  Production of the RANTES chemokine in delayed-type hypersensitivity reactions: involvement of macrophages and endothelial cells.

Authors:  O Devergne; A Marfaing-Koka; T J Schall; M B Leger-Ravet; M Sadick; M Peuchmaur; M C Crevon; K J Kim; T T Schall; T Kim
Journal:  J Exp Med       Date:  1994-05-01       Impact factor: 14.307

View more
  16 in total

1.  Card15 gene overexpression in mononuclear and epithelial cells of the inflamed Crohn's disease colon.

Authors:  D Berrebi; R Maudinas; J-P Hugot; M Chamaillard; F Chareyre; P De Lagausie; C Yang; P Desreumaux; M Giovannini; J-P Cézard; H Zouali; D Emilie; M Peuchmaur
Journal:  Gut       Date:  2003-06       Impact factor: 23.059

Review 2.  Ustekinumab in Crohn's disease: evidence to date and place in therapy.

Authors:  Tal Engel; Uri Kopylov
Journal:  Ther Adv Chronic Dis       Date:  2016-07-06       Impact factor: 5.091

3.  Current directions of biologic therapies in inflammatory bowel disease.

Authors:  Catherine Reenaers; Edouard Louis; Jacques Belaiche
Journal:  Therap Adv Gastroenterol       Date:  2010-03       Impact factor: 4.409

Review 4.  Interleukin-12 and Th1 immune response in Crohn's disease: pathogenetic relevance and therapeutic implication.

Authors:  Ilaria Peluso; Francesco Pallone; Giovanni Monteleone
Journal:  World J Gastroenterol       Date:  2006-09-21       Impact factor: 5.742

5.  Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab.

Authors:  Jacqueline M Benson; Clifford W Sachs; George Treacy; Honghui Zhou; Charles E Pendley; Carrie M Brodmerkel; Gopi Shankar; Mary A Mascelli
Journal:  Nat Biotechnol       Date:  2011-07       Impact factor: 54.908

Review 6.  Ustekinumab: A Review in Moderate to Severe Crohn's Disease.

Authors:  Yvette N Lamb; Sean T Duggan
Journal:  Drugs       Date:  2017-07       Impact factor: 9.546

Review 7.  Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders.

Authors:  Jacqueline M Benson; David Peritt; Bernard J Scallon; George A Heavner; David J Shealy; Jill M Giles-Komar; Mary Ann Mascelli
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

8.  Increased expression of IL-16 in inflammatory bowel disease.

Authors:  D Seegert; P Rosenstiel; H Pfahler; P Pfefferkorn; S Nikolaus; S Schreiber
Journal:  Gut       Date:  2001-03       Impact factor: 23.059

9.  An interleukin 12 p40-IgG2b fusion protein abrogates T cell mediated inflammation: anti-inflammatory activity in Crohn's disease and experimental colitis in vivo.

Authors:  A Stallmach; T Marth; B Weiss; B M Wittig; A Hombach; C Schmidt; M Neurath; M Zeitz; S Zeuzem; H Abken
Journal:  Gut       Date:  2004-03       Impact factor: 23.059

10.  Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease.

Authors:  S Kugathasan; L J Saubermann; L Smith; D Kou; J Itoh; D G Binion; A D Levine; R S Blumberg; C Fiocchi
Journal:  Gut       Date:  2007-08-06       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.